The Impact of Co-Infections for Human Gammaherpesvirus Infection and Associated Pathologies

Simple item page
dc.contributor.authorChinna, Prishanta
dc.contributor.authorBratl, Katrin
dc.contributor.authorLambarey, Humaira
dc.contributor.authorBlumenthal, Melissa J.
dc.contributor.authorSchäfer, Georgia
dc.date.accessioned2023-09-19T08:26:01Z
dc.date.available2023-09-19T08:26:01Z
dc.date.issued2023-08-22
dc.date.updated2023-09-08T12:44:38Z
dc.description.abstractThe two oncogenic human gammaherpesviruses Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV) cause significant disease burden, particularly in immunosuppressed individuals. Both viruses display latent and lytic phases of their life cycle with different outcomes for their associated pathologies. The high prevalence of infectious diseases in Sub-Saharan Africa (SSA), particularly HIV/AIDS, tuberculosis, malaria, and more recently, COVID-19, as well as their associated inflammatory responses, could potentially impact either virus’ infectious course. However, acute or lytically active EBV and/or KSHV infections often present with symptoms mimicking these predominant diseases leading to misdiagnosis or underdiagnosis of oncogenic herpesvirus-associated pathologies. EBV and/or KSHV infections are generally acquired early in life and remain latent until lytic reactivation is triggered by various stimuli. This review summarizes known associations between infectious agents prevalent in SSA and underlying EBV and/or KSHV infection. While presenting an overview of both viruses’ biphasic life cycles, this review aims to highlight the importance of co-infections in the correct identification of risk factors for and diagnoses of EBV- and/or KSHV-associated pathologies, particularly in SSA, where both oncogenic herpesviruses as well as other infectious agents are highly pervasive and can lead to substantial morbidity and mortality.
dc.identifierdoi: 10.3390/ijms241713066
dc.identifier.apacitationChinna, P., Bratl, K., Lambarey, H., Blumenthal, Melissa J., & Schäfer, G. (2023). The Impact of Co-Infections for Human Gammaherpesvirus Infection and Associated Pathologies. <i>International Journal of Molecular Sciences</i>, 24(17), 13066. http://hdl.handle.net/11427/38759en_ZA
dc.identifier.chicagocitationChinna, Prishanta, Katrin Bratl, Humaira Lambarey, Melissa J. Blumenthal, and Georgia Schäfer "The Impact of Co-Infections for Human Gammaherpesvirus Infection and Associated Pathologies." <i>International Journal of Molecular Sciences</i> 24, 17. (2023): 13066. http://hdl.handle.net/11427/38759en_ZA
dc.identifier.citationChinna, P., Bratl, K., Lambarey, H., Blumenthal, Melissa J. & Schäfer, G. 2023. The Impact of Co-Infections for Human Gammaherpesvirus Infection and Associated Pathologies. <i>International Journal of Molecular Sciences.</i> 24(17):13066. http://hdl.handle.net/11427/38759en_ZA
dc.identifier.risTY - Journal Article AU - Chinna, Prishanta AU - Bratl, Katrin AU - Lambarey, Humaira AU - Blumenthal, Melissa J. AU - Schäfer, Georgia AB - The two oncogenic human gammaherpesviruses Epstein-Barr virus (EBV) and Kaposi&rsquo;s sarcoma-associated herpesvirus (KSHV) cause significant disease burden, particularly in immunosuppressed individuals. Both viruses display latent and lytic phases of their life cycle with different outcomes for their associated pathologies. The high prevalence of infectious diseases in Sub-Saharan Africa (SSA), particularly HIV/AIDS, tuberculosis, malaria, and more recently, COVID-19, as well as their associated inflammatory responses, could potentially impact either virus&rsquo; infectious course. However, acute or lytically active EBV and/or KSHV infections often present with symptoms mimicking these predominant diseases leading to misdiagnosis or underdiagnosis of oncogenic herpesvirus-associated pathologies. EBV and/or KSHV infections are generally acquired early in life and remain latent until lytic reactivation is triggered by various stimuli. This review summarizes known associations between infectious agents prevalent in SSA and underlying EBV and/or KSHV infection. While presenting an overview of both viruses&rsquo; biphasic life cycles, this review aims to highlight the importance of co-infections in the correct identification of risk factors for and diagnoses of EBV- and/or KSHV-associated pathologies, particularly in SSA, where both oncogenic herpesviruses as well as other infectious agents are highly pervasive and can lead to substantial morbidity and mortality. DA - 2023-08-22 DB - OpenUCT DP - University of Cape Town IS - 17 LK - https://open.uct.ac.za PY - 2023 T1 - The Impact of Co-Infections for Human Gammaherpesvirus Infection and Associated Pathologies TI - The Impact of Co-Infections for Human Gammaherpesvirus Infection and Associated Pathologies UR - http://hdl.handle.net/11427/38759 ER -en_ZA
dc.identifier.urihttp://hdl.handle.net/11427/38759
dc.identifier.vancouvercitationChinna P, Bratl K, Lambarey H, Blumenthal Melissa J, Schäfer G. The Impact of Co-Infections for Human Gammaherpesvirus Infection and Associated Pathologies. International Journal of Molecular Sciences. 2023;24(17):13066. http://hdl.handle.net/11427/38759.en_ZA
dc.publisherMultidisciplinary Digital Publishing Institute
dc.publisher.departmentIntegrative Biomedical Sciences
dc.publisher.facultyHealth Sciences
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceInternational Journal of Molecular Sciences
dc.source.journalissue17
dc.source.journalvolume24
dc.source.pagination13066
dc.source.urihttps://www.mdpi.com/journal/ijms
dc.titleThe Impact of Co-Infections for Human Gammaherpesvirus Infection and Associated Pathologies
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijms-24-13066.pdf
Size:
1.22 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles